PTO/SB/08a (08-03) Approved for use through 07/31/2008, OMB 0651-0031

Substit	lute for form 1449A/F	то		Complete if Known			
INFO	RMATION F	1901 09	IIDE	Application Number	10/593,180		
STATEMENT BY APPLICANT				Filing Date	September 13, 2006		
OIAI	LINEIVI DI	ALLEG		First Named Inventor	Slade et al.		
				Art Unit	1626		
(4	(use as many sheets as necessary)			Examiner Name	Unknown		
Sheet	1	of	7	Allomey Docket Number	5062.03		

			U.S. PATENT	DOCUMENTS	
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2/Fitton)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Otted Document	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
		5,192,753	03-09-1993	McGeer et al.	
		5,434,170	07-18-1995	Andrulis	
		5,455,169	10-03-1995	Mullan	
		5,603,959	02-18-1997	Horrobin et al.	
		5,643,960	07-01-1997	Breitner et al.	
		5,695,774	12-09-1997	Clark	
		5,985,930	11-16-1999	Pasinetti	
		6,025,395	02-15-2000	Breitner et al.	
		6,160,018	12-12-2000	Wechter et al.	
		6,160,618	12-12-2000	Garner	
		6,184,248	02-06-2001	Lee et al.	
		6,255,347	07-03-2001	Xiaotao et al.	
		6,469,055	10-22-2002	Lee et al.	
		6,821,997	11-23-2004	Rodriguez	
		6,911,466	06-28-2005	Koo et al.	
		2005-0186559	08-25-2005	Koo et al.	
		2006-0004086	01-05-2006	Koo et al.	
		7 097 998	08.20.2006	Kon at al	

Examiner Initials'	Cte	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Country Code <sup>3</sup> Number <sup>6</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document		т
	1F	AU 01/257022	05-19-2005	Galasko et al.		Т
	2F	WO 01/78721	10-25-2001	Koo et al.		Т
	3F	WO 05/092062	03-21-2005	Slade et al.		I
						L

Examiner Signature		Date Considered	

"EXAMINER: Install Freference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy

SOURCE Intelligence consistent, whether one of clinical an outcombines with MEY-CR. Does to begin intelligence for an emissional and not consistent. Bitchin only PP 201 S. 1. Die Ford to search to clinical and the search to consistent and the searc

PTO/SB/08a (08-03)

Approved for use through 07/31/2005 OMB 0651-0001
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1649A		, p	is are required to respond to a collection of information unless is contains a valid CMB number.  Complete if Known			
IN	FORMATION D	ieci oe	HDE	Application Number	10/593,180		
	STATEMENT BY APPLICANT			Filing Date	September 13, 2006		
٠.	ATEMENT DI	AI I LIO		First Named Inventor	Slade et al.		
				Art Unit	1626		
	(use as many sheets as necessary)			Examiner Name	Unknown		
Sheet	2	of	7	Altomey Docket Number	5062.03		

## NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Examiner journal, senal, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where Initiale\* Nn published AKOHO et al., "A Study on Binding Modes of Nonsteroidal Anti-inflammatory Drugs to COX1 and 1A COX2 as Obtained by Dock4 0." J. Chem. Software, 1999, 5(3):1-13. AMIN et al., "The pleiotropic functions of aspirin; mechanisms of action," Cell. Mol. Life Sci., 1999. ANDREASEN et al., "Cerebrospinal Fluid β-Amyloid, 1425 in Alzheimer Disease," Arch. Neurol., 1999, 56:673-680 BAYLY et al., "Structure-Based Design of Cox-2 Selectivity Into Flurbiprofen," Bioor. Med. Chem. Left 1999, 9:307-312. BICKFORD et al., "Long-Term Treatment of Male F344 Rats with Deprenyl: Assessment of Effects 5A on Longevity, Behavior, and Brain Function," Neurobiology of Aging, 1997, 18(3):309-318. BLACKER et al., "The Genetics of Alzheimer Disease," Arch, Neurol., 1998, 55:294-298. RΑ BRAAK et al. "Neuropathological stageing of Alzheimer-related changes." Acta. Neuropathol. 7A 1991, 82:239-259. BREITNER et al., "Delayed onset of Alzherner's disease with nonsteroidal anti-inflammatory and 84 histamine H2 blocking drugs," Neurobiol. Aging, 1995, 16(4):523-30. RREITNER et al. "Inverse association of anti-inflammatory treatments and Alzheimer's 9A disease:Initial results of a co-twin control study", Neurology, February 1994, 44:227-232. CAMMISULI et al., "Effects of extended electrical kindling on exploratory behavior and spatial 10A learning," Behav. Brain Res., 1997, 89:179-190. CANAPARO et al., "Determination of Ibuprofen in human plasma by high-performance liquid chromatography: validation and application in pharmacokinetic study," Biomed, Chromatogr., 2000. 14-219-226 CHEN et al., "A learning deficit related to age and 8-amyloid plagues in a mouse model of 12A Alzheimder's disease " Nature 2000 408:975-979 CITRON et al., "Evidence that the 42- and 40-amino acid forms of amyloid 8 protein are generated 13A from the β-armyloid precursor protein by different protease activities," Proc. Natl. Acad. Sci. USA, 1996. 93:13170-13175 COMBS et al., "Inflammatory Mechanisms in Alzheimer's Disease. Inhibition of B-Amyloid-14A Stimulated Proinflammatory Responses and Neuroloxicity by PPARy Agonists," J. Neurosci., 2000. 20(2):558-567

Examiner

An advantage of the control of the c

PTO/S8/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Palent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449A	/PTO		Complete if Known			
INI	FORMATION F	nisci os	HIDE	Application Number	10/593,180		
	STATEMENT BY APPLICANT			Filing Date	September 13, 2006		
٠.	ATEMENT DI	AI I LIC		First Named Inventor	Slade et al.		
				Art Unit	1626		
	(use as many sheets as necessary)			Examiner Name	Unknown		
Sheet	3	af	7	Allomey Docket Number	5062.03		

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, oily and/or country where publisher.	7
	15A	CORTON et al., "Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators," Annu. Rev. Pharmacol., 2000, 40:491-518.	Γ
	16A	COTRAN et al., Pathologic Basis of Disease, Sixth Edition, 1999, W.B. Saunders Company, Philadelphia, p. 1332, Table 30-2.	Γ
	17A	CRONSTEIN et al., "Targets for Antiinflammatory Drugs," Annu. Rev. Pharmacol. Toxicol., 1995, 35:449-462.	Γ
	18A	CRYER et al., "Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs," Am. J. Med., 1998, 104:413-421	Γ
	19A	DEWITT, "Cox-2-Selective Inhibitors: The New Super Aspirins," Mol. Pharmacol., 1999, 55(4):625-631.	Г
	20A	DUBOIS et al., "Cyclooxygenase in biology and disease," FASEB J., 1998, 12:1063-1073.	T
	21A	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo," J. Clin. Invest., 2003, 112(3):440-449.	Г
	22A	FOLSTEIN et al., "Mini-Mental State" – A Practical Method for Grading the Cognitive State of Patients for the Clinician," J. Psychiat, Res., 1975, 12:189-198.	Γ
	23A	FRAUTSCHY et al., "Animal Model – Microglial Response to Amyloid Plaques in APPsw Transgenic Mice," Am. J. Pathol., 1998, 152:307-317.	Γ
	24A	GALASKO et al., "An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease," Alzheimer Disease and Associated Disorders, 1997, 11(Suppl. 2):S33-S39.	Γ
	25A	GALASKO et al., "High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype," Arch. Neurol., 1998, 55:937-945.	Γ
	26A	HALLIDAY et al., "Alzheimer's Disease and Inflammation: A Review of Cellular and Therapeutic Mechanisms," Clin. Exp. Pharmacol. Physiol., 2000, 27:1-8.	Γ
	27A	HAUGABOOK et al., "Reduction of Aβ accumulation in the Tg2576 animal model of A/zheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin," <u>FASEB J.</u> , 2000, 16-18.	Γ
	28A	HE et al. "PPAR6 is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs," Cell, 1999, 99:335-345	Γ
	29A	HIGAKI et al., "Inhibition of β-Arryloid Formation Identifies Proteolytic Precursors and Subcellular Site of Catabolism," Neuron, 1995, 14:651-659.	Γ
	30A	HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," Science, 1996, 274 99-102.	Γ
vaminor	_	Data	

"EXAMINER: Initial if reference considered, whether or not obtain is in conformance with MPEP 609. Draw line through chalcon if not in conformance and not considered. Include copy

\*\*COMPUTE: The first definance considered, used are of an excess in a commence was the Value. Let us through costant data of commence are consequently an experience of a commence are consequently an experience of a commence are consequently an experience of a consequently an experience of a consequently an experience of a VPT ALL. The contention is required to detail or not one and week tip to public data in the proof by the UCEPT to proceed a specified or conformation are promoted by the UCEPT to proceed a provided and an experience of a VPT ALL. The content is an extended to the Annual complex, which are the property and such experience are contention as or contention and an experience of a very content of a very contention and an experience of a very contention and an experience of a very contention and an experience of a very content of a ver

PTO/S8/08a (08-03) Approved for use through 07/31/2008, CMB 0651-0031

Sui	bstitute for form 1449A	РТО		Complete if Known			
INEC	DRMATION D	ieci ne	IIDE	Application Number	10/593,180		
	STATEMENT BY APPLICANT			Filing Date	September 13, 2006		
OIA	TEMENT DI	AI I LIO		First Named Inventor	Slade et al.		
				Art Unit	1626		
	(use as many sheets as necessary)			Examiner Name	Unknown		
Sheet	4	af	7	Attorney Docket Number	5062.03		

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Ote No 1	include name of the surfor (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, calalog, etc.), date, pageds), volume issue number(s), publisher, oily and/or country where published.	T <sup>2</sup>					
	31A	KALGUTKAR et al., "Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsterioridal antinifiammatory drugs to potent and highly selective COX-2 inhibitors," Proc Natl Acad. Sci. USA, 2000, 97(2):925-930.						
	32A	KALGUTKAR et al., "Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors," J. Med. Chem., 2000, 43:2860-2870.						
	33A	KATO et al., "Oyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes," Journal of Pharmacy and Pharmacology, 2001, 53:1679-1685.						
	34A	KAWARABAYASHI et al., "Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease," J. Neurosci., 2001, 21(2):372-381.						
	35A	KHACHATURINAN, "Diagnosis of Alzheimer's Disease," Arch. Neurol,, 1985, 42:1097-1105.						
	36A	KITAMURA et al., "Increased Expression of Cyclooxygenases and Peroxisome Proliferator- Activated Receptor-y in Alzheimer's Disease Brains," Biochem. Biophys. Res. Comm., 1999, 254:382-384.						
	37A	KLAFKI et al., "The Carboxyl Termini of β-Armyloid Peptides 1-40 and 1-42 Are Generated by Distinct γ-Secretase Activities," J. Biol. Chem., 1996, 271(45):28655-28659.						
	38A	KOO et al., "Evidence That Production and Release of Amyloid β-Protein Involves the Endocytic Pathway," J. Biol. Chem., 1994, 269(26):17386-17389.						
	39A	KOO et al., "Trafficking of cell-surface amyloid β-protein perecursor," J. Cell Sci., 1996, 109:991-998.						
	40A	KOPAN et al., "Signal transduction by activated mNotch: Importance of proteolytic processing and its regulation by the extracellular domain," Proc. Natl. Acad. Sci. USA, 1996, 93:1683-1688.						
	41A	KOUP et al., "A Single and Multiple Dose Pharmacokinetic and Metabolism Study of Meclofenamate Sodium," Biopharm. Drug Dispos., 1990, 11:1-15.						
	42A	LEE et al., "Regulation of APP Synthesis and Secretion by Neurommunophilin Ligands and Cyclooxygenase Inhibitors", Annals New York Academy of Sciences, 2000, 920:261-268.						
	43A	LEWIS et al., "Neurofibrillary tangles, armyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein," <i>Nature Genetics</i> , 2000, 25:402-405.						
	44A	LIM et al., "Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease," J. Neurosci., 2000, 20(15):5709-5714.						
	45A	LU et al., "A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor," Nature Medicine, 2000, 6(4):397-404.						
	46A	MCGEER et al., "Anti-inflammatory drugs and Alzheimer disease," Lancet, 1990, 335(8696):1037						
Examiner Signature		Date Considered						

EXAMINER: Initial if reference considered, whether or not obtains an conformence with MPEP 609. Drawlere through chaton if not in conformence and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1 97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.54. This collection is estimated to take 2 hours to complete, including performing, preparing, and submitting the completed application form to HIGH USPTO. These where you can be not value on an account of the second on the amount of them you require to complete the form of the second on the amount of them you require to complete the form of the second on the second of them you require to complete the form of the second of

PTO/SB/08a (06-03) Approved for use through 07/31/20PTO/SB/08a (08-03)

Approved for use through 07731/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Si	ubstitute for form 1449A	MPTO .		Complete if Known		
INF	ORMATION D	neci ne	IIDE	Application Number	10/593,180	
	STATEMENT BY APPLICANT			Filing Date	September 13, 2006	
017	VIEWEIVI DI	Al I LIO		First Named Inventor	Slade et al.	
				Art Unit	1626	
	(use as many sheets as necessary)			Examiner Name	Unknown	
iheet	5	of	7	Altomey Docket Number	5062.03	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No 1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or occurity where publisher.	Τ³
	47A	MCGEER et al., "Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies," Neurology, 1996, 47(2):425-32.	
	48A	MCKHANN et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology, 1984, 34(7):393-941.	Γ
	49A	MCLENDON et al., "Cell-free assays for γ-secretase activity," FASEB J., 2000, 14(15):2393-2396	Г
	50A	MIRRA et al., "Making the Diagnoss of Alzheimer's Disease – A Primer for Practicing Pathologists," Arch. Pathol. Lab. Med., 1993, 117:132-144.	Г
	51A	MIRRA et al., "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD),"  Neurology, 1991, 41:479-486.	
	52A	MOHS, "Comprehensive and Neuropsychologic Evaluations – The Alzheimer's Disease Assessment Scale," International Psychogeniatrics, 1996, 8(2):195-203.	
	53A	MONTINE et al., "Increased CSF F <sub>2</sub> -isoprostane concentration in probable AD," Neurology, 1999, 52:562-565.	
	54A	MURPHY et al., "A Simple and Rapid Test of Sensorimotor Function in the Aged Rat," Neurobiology of Learning and Memory, 1995, 64:181-186.	Γ
	55A	MURPHY et al., "Presentin 1 Regulates Pharmacologically Distinct γ-Secretase Activities," J. Biol. Chem., 2000, 275(34):26277-26284.	Γ
	56A	NETLAND et al., "Indomethacin Reverses the Microglial Response to Amyloid β-Protein", Neurobiology of Aging, February 1998, 19(3):201-4.	Γ
	57A	PERETTO et al., "Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid <sub>1-42</sub> Secretion", Journal of Medicinal Chemistry, March 21, 2005, pages A-P.	Γ
	58A	PEREZ et al., "Mutagenesis Identifies New Signals for β-Amyloid Precursor Protein Endocytosis, Turnover, and the Generation of Secreted Fragments, Including Aβ42," J. Biol. Chem., 1999, 274(27) 1895-1.18956	
	59A	PEROLA et al., "Successful Virtual Screening of a Chemical Database for Farnesyltransferase Inhibitor Leads," J. Med. Chem., 2000, 43:401–408.	
	60A	PIAZZA et al., "Antineoplastic Drugs Sulndac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis," Cancer Res., 1995, 55'3110-3116.	
	61A	RICK et al., "Short Intertrial Intervals Impair Water Maze Performance in Old Fischer 344 Rats," J. Geronfol Biol. Sci., 1996, 51A(4):B253-B260.	Γ

Signature	Considered
"FYAMINES" Inches of reference considered, whether or and relation is in confirmance with MEED SER.	Drawing french claim find a confurmance and not considered. Include con-

of his form of the communication is against.

If his form of the communication is against.

If his form of the communication is against.

If his form of the communication is against a communication of the communication

PTO/SB/08a (08-03) Approved for use through 07/31/2008, OMB 0851-0031

Approved for use through 07/31/2008, OMB 0851-0031
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Traclemank Office, U.S. DEPARTMENT OF COMMERCE
U.S. Palent and U.S. Palen

Substitute for form 1449AMPTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known			
		Application Number	10/593,180		
		Filing Date	September 13, 2006		
		First Named Inventor	Slade et al.		
(use as many sheets as necessary)				Art Unit	1626
			0	Examiner Name	Unknown
Sheet	6	af	7	Allomey Docket Number	5062 03

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tills of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, oily and/or country where publisher.	T2
	62A	RIENDEAU et al., "Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti- inflammatory drugs (NSAIDs) and selective COX2 inhibitors, using sensitive microsomal and platelet assays," Can. J. Physiol. Pharmacot., 1997, 75:1088-1095.	
	63A	ROGERS et al., "Clinical trial of indomethacin in Alzheimer's disease", Neurology, August 1993, 43:1609-1611.	Г
	64A	SAGI et al., "The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of kB Kinase, and NFkB, Do Not Reduce Amylord β42 Production," J. Brol. Chem., 2003, 278(34):31825-31830.	
	65A	SISODIA et al., "Identification and Transport of Full-Length Amyloid Precursor Proteins in Rat Peripheral Nervous System," J. Neurosci., 1993, 13(7):3136-3142.	Γ
	66A	SMITH et al., "Cycloxygenases: Structural, Cellular, and Molecular Biology," Annu. Rev. Biochem., 2000, 69:145-182.	Г
	67A	SUNDERLAND et al., "Longitudinal Stability of CSF Tau Levels in Alzheimer Patients," Blol. Psychiatry, 1999, 46:750-755.	
	68A	SUZUKI et al., "An Increased Percentage of Long Arryloid β Protein Secreted by Familial Amyloid β Protein Precursor (βΑΡΡ <sub>717</sub> ) Mutants," Science, 1994, 264:1336-1340.	Г
	69A	WANG et al., "The Profile of Soluble Amyloid β Protein in Cultured Cell Media," J. Biol. Chem., 1996, 271(50):31894-31902.	
	70A	WEGGEN et al., "A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity," Nature, 2001, 414:212-216.	Г
	71A	WEGGEN et al., "A\$42-lowering Nonsteroidal Anti-Inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and Ertb8-4 Receptor and Signaling through the APP Intraediustr Domain," J. Biot. Chem., 2003, 278(33) 30748-30754.	
	72A	WEGGEN et al., "Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity," J. Biol. Chem., 2003, 278(34):31831-31837.	
	73A	WILTFANG et al., "Improved electrophoretic separation and immunoblotting of beta-amyloid (Aβ) peptides 1-40, 1-42, and 1-43," Electrophoresis, 1997, 18:527-532.	Γ
	74A	WOLFE et al., "A Substrate-Based Diffuoro Ketone Selective Inhibits Alzheimer's γ-Secretase Activity," J. Med. Chem., 1998, 41:6-9.	Г
	75A	WOLFE et al., "Are Presenilins Intramembrane-Cleaving Proteases? Implications for the Molecular Mechanism of Alzheimer's Disease," Biochemistry, 1999, 38(35):11223-11230.	Г
	76A	YUAN et al., "Recombinant adenownus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons," J. Neurosci. Methods, 1999, 88:45-54.	Γ

Examiner
Signature
Date
Considered

\*\*EXAMONE\*\*, Tritle if informac considered, whether or not clother in in continuous with METP 450. Does the though cited or find in continuous end or considered. Problems

<sup>\*\*</sup>COUNTED\*\* Their distinance consideration, whether and relations to reduce the contraction of the counter their contractions of their counter their contractions of their counter their counterparts and their counterparts are contracted to the counterparts are contracted to the counterparts are contracted to their counterparts are contracted to their counterparts are contracted to the counterparts are counterparts are contracted to the counterparts are contracted to t

should be sent to the Chief Information Officer, U.S. Peterti and Trademant Officer, U.S. Department of Commerce, P.O. Box 1456, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED PORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1456, Alexandria, VA 22313-1450.

DT/VERIDRA (08-03) 31 E

Approved for use through 07/31/2005	OMB 0651-003
U.S. Palent and Trademark Office, U.S. DEPARTMENT	OF COMMERC
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a va-	id OMB numbe

Substitute for form 1449APTO INFORMATION DISCLOSURE		Complete if Known			
		Application Number	10/593,180		
STATEMENT BY APPLICANT	Filing Date	September 13, 2006			
OTATEMENT DI ATTECANI		First Named Inventor	Slade et al.		
(use as many sheets as necessary)				Art Unit	1626
				Examiner Name	Unknown
Sheet	7	of .	7	Allomey Docket Number	5062.03

		NON PATENT LITERATURE DOCUMENTS	
xamner initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page;(s), volume-issue number(s), publisher, oty and/or country where publisher.	T
	77A	ZHANG et al., "Calpain Inhibitor I Increases β-Armyloid Peptide Production by Inhibiting the Degradation of the Substrate of Y-Secretase", The Journal of Biological Chemistry, March 26, 1999, 274(13) 9969-8972.	Ī
	78A	ZHANG et al., "Malignant Transformation and Antineoplastic Actions of Norsterouts' Antinflammatory Drugs (NSAIDs) on Cyclooxygenase-null Embryo Fribroblasts," J. Exp. Med., 1999, 190(4):451-459.	Ī
	$\vdash$		ł
	F		ł
	Н		ł
			I
	L		1
	⊢		1
	$\vdash$		t
			İ
			l
			١

\*EXAMPLE: Initial if reference considered, whether or not classon as in conformance with MPEP SES. Draw less through classon if not in conformance and not considered. Include copy of this form with next communication to applicant.

or is our warmen communication appearant.

(Application super debtion designation marber (optionsity): 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CPR 1.57 and 1.53. The information is impaired to obtain or making a basic layer by the LEPPL optionsisty is applicated. Destine or making a basic very layer by 1.57 CPR 1.57 and 1.53. The information is impaired to obtain or making a basic very layer by 1.57 CPR 1.57 and 1.57 The information is impaired by 1.57 CPR 1.57 and 1.57 The information is impaired by 1.57 CPR 1.57 and 1.57 The information is impaired by 1.57 CPR 1.57 The information is impaired by 1.57 CPR 1.57 The information is impaired by 1.57 The information is information in information in information in information is information in information in information in information in info

the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to compiles this form entire suggestions for viscoring this burden, should be sent to the Chief Information Officer, U.S. Prietral and Taskmank Office, U.S. Department of Commence, P.O. Son 1469, Westerdin, V.A. 22313-1450. DO NOT SENO FEES OR COMPLIETED FORWARD TO THIS ACCOUNT. SEND FEES OR COMPLIED FOR THIS ACCOUNT. SEND FEES OR COMPLIED